Medline Inc. (MDLN)
NASDAQ: MDLN · Real-Time Price · USD
35.31
-0.15 (-0.42%)
At close: Oct 21, 2026, 4:00 PM EDT
35.30
-0.01 (-0.03%)
Pre-market: Oct 22, 2026, 4:09 AM EDT
Medline Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, Medline stock has a consensus rating of "Buy" and an average price target of $44.42. The average 1-year stock price forecast is 25.80% higher than the current stock price, while the lowest is $34 (-3.71%) and the highest is $55 (+55.76%).
Price Target: $44.42 (+25.80%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Medline stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 16 | 16 | 16 | 16 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 27 | 27 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $45 → $43 | Buy | Maintains | $45 → $43 | +21.78% | Oct 9, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $43 | Buy | Maintains | $43 | +21.78% | Oct 8, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $46 | Buy | Maintains | $46 | +30.27% | Oct 7, 2026 |
| UBS | UBS | Buy Reiterates $45 → $43 | Buy | Reiterates | $45 → $43 | +21.78% | Sep 25, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 23, 2026 |
Financial Forecast
Revenue This Year
31.23B
from 28.43B
Increased by 9.84%
Revenue Next Year
33.68B
from 31.23B
Increased by 7.85%
EPS This Year
1.55
from 1.32
Increased by 17.53%
EPS Next Year
1.58
from 1.55
Increased by 1.63%
EPS and Forward PE are based on non-GAAP adjusted numbers.